Celon Pharma has signed a letter of intent with Tarchominskie Zakłady Farmaceutyczne in the field of R&D and production of drugs based on modern technologies (m-RNA), a platform of highly active drugs, with particular emphasis in the areas of infectious diseases, oncology and metabolic diseases.
Celon Pharma is an integrated biopharmaceutical company engaged in research, development, production and sale of pharmaceutical products. It made its debut on the WSE main market in 2016.
Tarchomińskie Zakłady Farmaceutyczne “Polfa” Spółka Akcyjna is one of the oldest pharmaceutical companies in Europe. It has been operating on the market since 1823. The State Treasury is the majority shareholder. The plant has about 30 production lines producing over 300 products, which means about 20 million packages of drugs per year.